Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
109 hedge funds and large institutions have $495M invested in Albireo Pharma Inc in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 39 reducing their positions, and 8 closing their positions.
1,633% more call options, than puts
Call options by funds: $8.42M | Put options by funds: $486K
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
37% more capital invested
Capital invested by funds: $362M → $495M (+$133M)
14% more funds holding
Funds holding: 96 → 109 (+13)
23% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.7M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$12.9M |
| 3 |
O
OrbiMed
New York
|
+$5.68M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$5.1M |
| 5 |
CC
Chicago Capital
Chicago,
Illinois
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$14M |
| 2 |
Millennium Management
New York
|
-$4.6M |
| 3 |
Goldman Sachs
New York
|
-$3.75M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.01M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.46M |
ALBO Hedge Fund Activity: Q1 2022 in Review
109 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2022, worth a combined $495M — up 37% from $362M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ALBO positions and 8 closed out — a net gain of 13 holders — while 30 added to existing stakes and 39 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.7M. The largest seller was Artal Group, exiting entirely with an estimated $14M sold.
- 109 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2022, up from 96 in Q4 2021.
- Funds reported $495M of Albireo Pharma Inc stock for Q1 2022, up 37% quarter-over-quarter.
- 21 funds opened new Albireo Pharma Inc positions in Q1 2022 and 8 closed out, a net change of +13 holders.
- The largest Albireo Pharma Inc buyer in Q1 2022 was Tang Capital Management, an estimated $13.7M added.
- The largest Albireo Pharma Inc seller in Q1 2022 was Artal Group, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2022.